Treatment of Common Prostate Cancer
Treatment of Common Prostate Cancer
Complete the form below and we will email you a PDF version of "Treatment of Common Prostate Cancer"
Prostate cancer patients and their doctors may want to think twice about the best timing for chemotherapy or radiation therapy in conjunction with a common nonsurgical treatment, based on international research findings led by UT Southwestern Medical Center investigators.
Researchers using mouse models found that many medical androgen deprivation therapies (ADTs) – the most commonly used nonsurgical treatments for prostate cancer – may suppress responses patients’ adaptive immune, preventing immunotherapies from working if both treatments are used but not sequenced properly. ADTs are anti-hormone therapies that decrease the body’s levels of androgens, the type of hormone that is required for prostate cancer to survive and grow.
The study findings were published this week in Science Translational Medicine. “Medical ADTs have been used for a half century to treat prostate cancer, and promising clinical results for cancer immunotherapy have led to attempts to combine it and other standard-of-care therapies with immunotherapy to treat the disease,” said senior author and principal investigator.
Relapse of prostate tumors, however, has been a major problem. “While surgical ADT castration – works well with immunotherapy, we determined that some androgen receptor antagonists could reduce the T-cell response against prostate cancer, leading to early tumor relapse,” said Dr. Fu, who holds the Mary Nell and Ralph B. Rogers Professorship in Immunology and also is a member of the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern.
In other words, the suppressed immune response caused by medical ADTs block the efficacy of immunotherapy and leads to the relapses in cancer commonly seen in clinical trials. “Our study shows that in some patients, this poor response could also be due to the radiation or chemotherapy itself suppressing the immune response,” Dr. Fu explained.
“These treatments may reduce the tumor burden in the short term, but at the same time, they can suppress the immune response – and because they don’t kill every cancer cell, resistant clones will be selected, especially when the body’s immune response is not mobilized, and the tumor will relapse much more aggressively.
Careful regulation of the timing, types, and dosage of anti androgens used with immunotherapy are key to maximizing the anti-tumor effects of combination therapy, the study indicates. “The findings also highlight an underappreciated mechanism of androgen receptor (AR) antagonist-mediated immune suppression and provide a new strategy to enhance the immune response and perhaps prevent or delay the relapse of advanced prostate cancer,” Dr. Fu said.
More studies are needed, Dr. Fu said, but the upshot is that some chemotherapies and radiation therapies should not be used concurrently with immunotherapies. “We hope that our findings will cause physicians to think twice before starting chemotherapy or radiation on their cancer patients, to consider the best way to combine them with immunotherapies,” he said. “The idea is to kill the tumor cells while also considering whether these therapies are suppressing or activating the immune system.”
Lead author of the study was Yang Pu, a visiting junior researcher in Pathology. Researchers from the University of Chicago, South China University of Technology, Chinese Academy of Sciences, and Shanghai Jiao Tong University in China also contributed. The study was supported by grants from the National Institutes of Health and China’s Ministry of Science and Technology.
The Harold C. Simmons Comprehensive Cancer Center is the only NCI-designated Comprehensive Cancer Center in North Texas and one of just 45 NCI-designated Comprehensive Cancer Centers in the nation. The Simmons Comprehensive Cancer Center includes 13 major cancer care programs with a focus on treating the whole patient with innovative treatments, while fostering groundbreaking basic research that has the potential to improve patient care and prevention of cancer worldwide.
In addition, the Center’s education and training programs support and develop the next generation of cancer researchers and clinicians. The Simmons Cancer Center is among only 30 U.S. cancer research centers to be named a National Clinical Trials Network Lead Academic Participating Site, a prestigious new designation by the NCI, and the only cancer center in North Texas to be so designated.
The designation and associated funding is designed to bolster the cancer center’s clinical cancer research for adults and to provide patients access to cancer research trials sponsored by the NCI, where promising new drugs often are tested.